NRD
COGT icon

Nebula Research & Development’s Cogent Biosciences COGT Stock Holding History

Nebula Research & Development’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-51,972
Closed -$306K – 779
2023
Q4 		$306K Buy
51,972
+40,523
+354% +$311K 0.09% 429
2023
Q3 		$112K Buy
11,449
+142
+1% +$1.68K 0.06% 446
2023
Q2 		$134K Buy
+11,307
New +$130K 0.1% 290

Other funds holding COGT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Nebula Research & Development's COGT Position: Q1 2024 in Review

Nebula Research & Development sold out of Cogent Biosciences (COGT) in Q1 2024, closing a stake of 51,972 shares — an estimated $306K sold.

Nebula Research & Development first reported a position in COGT in Q2 2023 and held it in 3 quarters. The position peaked at $306K in Q4 2023. 146 funds tracked by Wall St. Rank hold COGT as of Q1 2024.

  • Nebula Research & Development reported no remaining Cogent Biosciences position as of Q1 2024 after selling out during the quarter.
  • Nebula Research & Development sold 51,972 Cogent Biosciences shares in Q1 2024, an estimated $306K.
  • Nebula Research & Development first reported a position in Cogent Biosciences in Q2 2023 and held it in 3 quarters.
  • Nebula Research & Development's Cogent Biosciences position peaked at $306K in Q4 2023.
  • 146 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2024.

Based on Nebula Research & Development's 13F filing for Q1 2024, filed 15 May 2024.